The life sciences outlook for 2026 is being shaped by three interlocking forces, writes Paul Hughes, Managing Director, Life Sciences & Technology, BDO LLP.
A spike in M&A activity and stock prices have pulled biotech out of a yearslong downturn. But regulatory tumult and fierce ...
Securities.io maintains rigorous editorial standards and may receive compensation from reviewed links. We are not a registered investment adviser and this is not investment advice. Please view our ...
Vertex Pharmaceuticals' late-stage pipeline. Vertex Pharmaceuticals' strategy is to develop medicines in areas with high ...
PHOENIX, Ariz., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Breakthru Medicine emerges from stealth with the close of a $60M Series A ...
The NBA flagged a strong surge in microbial innovation across healthcare, agriculture, and industrial applications.
WuXi Biologics, a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc., a global clinical-stage biotechnology company advancing next-generation ...
Guadalupe Hayes-Mota is director, bioethics at the Markkula Center for Applied Ethics. Views are his own. This article, "Using the CARES Framework to Build Ethical Biotech Startups" , originally ...
But deciding if it's a good buy takes a little more looking.
Pharmaceutical Technology on MSN
UK biotechs suffered restricted financing in 2025
Despite a lacklustre year for UK biotech funding, M&A pickup and trade deals could drive growth rebound.
RTW Biotech Opportunities’ (or RTW Bio as we call it) evergreen structure provides a long-term base, giving us the ...
The Drug Information Association (DIA) today announced the launch of DIA ASCENT, a new global platform designed to support early-stage biotechnology drug development innovation, along with its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results